gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CUEHealthcarePharmaceuticals

Cue Biopharma, Inc. (CUE)

$19.84−4.89%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$19.84▼ 8.30% in range
Nov 4, 2025Low $5.31 · High $498.78Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Cue Biopharma closed at $19.84 on Nov 4, down 4.89%, 96.0% below its 52-week closing high. Volume of 169.0K shares was 1.06× its 20-day average (close to normal).

Split-adjusted performance: -14.3% over one month, -41.6% over six months, -7.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $7.88M, up 166.7% from a year earlier, with a net margin of -1943.2%.

Short interest was 792.6K shares at the Oct 15 settlement, up 12.9% from the prior report (12.2% of float, 3.7 days to cover).

Market cap$144.1M7.3M shares
Revenue · quarter$7.9M+166.7% YoY
Diluted EPS$-24.14—
P/E · TTM—P/S 3.8×
Net margin-1,943.2%Gross 100.0%
Dividend yieldNone
52-week range5.31 – 498.78−96.0% from high
Volume169.0K1.06× 20-day avg
Volatility · 60d137.7%Annualised
Short % of float12.2%3.7 days to cover
Net cash$16.4MCash $17.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.2%1M −14.3%3M −26.5%6M −41.6%YTD +116.5%1Y −7.8%3Y −65.6%5Y −94.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum32
Revenue growth88
Net margin13
Value (low P/E)—
Size44

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short792.6K+12.9% vs prior
Days to cover3.7Settled Oct 15
% of float12.2%
Short vol. 10d59.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CUECue Biopharma$19.84−4.89%−41.6%+166.7%−1943.2%—$144.1M
MGNXMacroGenics$2.31−0.86%−23.3%+378.0%59.4%—$147.1MCompare
RNAAtrium Therapeutics$8.68−0.46%−33.7%−21.9%−672.0%—$148.5MCompare
PYXSPyxis Oncology$1.66+1.22%−27.8%−100.0%——$138.5MCompare
SPRBSpruce Biosciences$46.61+8.88%−19.5%———$134.0MCompare
DERMJourney Medical$4.73+1.94%−9.2%+18.9%−1.7%—$133.5MCompare
ANTXAN2 Therapeutics$4.25+1.67%−8.6%———$160.4MCompare
YARWYarrow Bioscience$14.91−18.84%————$125.8MCompare
FHTXFoghorn Therapeutics$2.10−1.41%−55.1%+112.7%−44.7%—$124.7MCompare

News about Cue Biopharma

All news →
Cue Biopharma Announces $50.0 Million Private PlacementGlobeNewswire Inc. · Jul 10, 2026▲ PositiveCue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · May 7, 2026▲ PositiveCue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License AgreementGlobeNewswire Inc. · Apr 8, 2026▲ Positive

Quick answers

What does Cue Biopharma do?
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases.
What is CUE's market cap?
$144.13M, based on the Nov 4 close of $19.84.
Does Cue Biopharma pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CUE is sold short?
792.6K shares, 12.2% of float, as of Oct 15, 2026.
What sector is CUE in?
Healthcare, in the Pharmaceuticals industry.

About Cue Biopharma

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

HQ: Boston, MA29 employeesListed Jan 2, 2018cuebiopharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology